Table 1 Demographic and baseline characteristics of patients
Characteristic | Secukinumab 300 mg (N = 139) | Secukinumab 150 mg (N = 138) | Placebo (N = 137) |
|---|---|---|---|
Age (years), mean (SD) | 49.3 (12.9) | 50.1 (11.7) | 50.1 (12.6) |
Male, n (%) | 67 (48.2) | 61 (44.2) | 59 (43.1) |
Race, n (%) | |||
White | 130 (93.5) | 129 (93.5) | 133 (97.1) |
American Indian or Alaska Native | 0 | 2 (1.4) | 0 |
Asian | 3 (2.2) | 2 (1.4) | 4 (2.9) |
Other | 6 (4.3) | 5 (3.6) | 0 |
Weight (kg), mean (SD) | 87.1 (19.4) | 87.1 (20.0) | 82.6 (18.5) |
Number of previous anti-TNF treatments for PsA, n (%) | |||
0 | 95 (68.3) | 94 (68.1) | 93 (67.9) |
1 | 19 (13.7) | 22 (15.9) | 20 (14.6) |
≥ 2 | 25 (18.0) | 22 (15.9) | 24 (17.5) |
Time since diagnosis of PsA (years), mean (SD) | 8.3 (9.2) | 7.7 (8.5) | 6.6 (6.9) |
MTX use at randomization, n (%) | 70 (50.4) | 59 (42.8) | 68 (49.6) |
Systemic glucocorticoid use at randomization, n (%) | 23 (16.5) | 24 (17.4) | 32 (23.4) |
Anti-TNF-naïve, n (%) | 95 (68.3) | 94 (68.1) | 93 (67.9) |
Patients with specific disease characteristics, n (%) | |||
Psoriasis ≥ 3% of BSA | 62 (44.6) | 68 (49.3) | 59 (43.1) |
Presence of dactylitis | 46 (33.1) | 36 (26.1) | 36 (26.3) |
Presence of enthesitis | 88 (63.3) | 95 (68.8) | 98 (71.5) |
Disease and quality-of-life scores, mean (SD) | |||
TJC (78 joints) | 19.7 (14.8) | 23.3 (18.1) | 21.9 (16.2) |
SJC (76 joints) | 8.9 (6.4) | 11.2 (9.2) | 10.3 (8.6) |
DAS28-CRP | 4.5 (1.0) | 4.6 (1.1) | 4.7 (1.1) |
PASIa | 10.1 (8.6) | 8.8 (6.4) | 10.4 (9.0) |
Physician’s global assessment (VAS) | 51.8 (19.7) | 55.2 (16.7) | 54.8 (18.1) |
HAQ-DI | 1.1 (0.7) | 1.2 (0.6) | 1.2 (0.6) |
PsA pain (VAS) | 54.8 (23.8) | 54.4 (21.4) | 53.3 (23.8) |
Patient’s global assessment (VAS) | 59.9 (20.8) | 59.8 (22.1) | 60.6 (20.9) |
SF-36 PCS | 39.2 (8.4) | 37.9 (7.6) | 37.4 (8.5) |